Related Articles
Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review)
Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells
Precision medicine for human cancers with Notch signaling dysregulation (Review)
Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)